Stockwatch: Summer squall amplifies bad news
This article was originally published in Scrip
August was a disconcerting month for investors as jitters continue in the world's financial markets. With investors looking for safe havens for their money it was not surprising to see a wholesale sell-off of biotech stocks in the week up to 19 August, with those outside the US taking the biggest hits. Moreover, gold prices edging upwards it was also clear that big pharma stocks are no longer considered the ports in which investors can weather a storm.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.